基于图谱的宫颈癌活跃骨髓保护IMRT可行性研究
本研究纳入62例宫颈癌患者(训练集32例、测试集30例),比较基于图谱的活跃骨髓(ABMAtlas)与个体化ABM(ABMCustom)保护IMRT的剂量学结果。ABMAtlas与ABMCustom体积无显著差异(p=0.90),平均Dice系数0.75。在30例测试患者中,ABMAtlas保护IMRT获得良好靶区覆盖和正常组织保护,未降低ABMCustom剂量(平均剂量29.4Gy vs 27.1Gy vs 26.9Gy,p=0.10),但PTV覆盖和肠道保护略降低。结论认为基于图谱的ABM保护IMRT临床可行,可能无需个体化ABM保护。
要点
- ABMAtlas与ABMCustom体积无显著差异,平均Dice系数0.75,一致性良好。
- ABMAtlas保护IMRT未降低ABMCustom平均剂量(29.4Gy vs 27.1Gy vs 26.9Gy,p=0.10)。
- ABMAtlas保护IMRT的PTV覆盖和肠道保护略低于PBM或ABMCustom保护计划。
核心结论
- 基于图谱的活跃骨髓保护IMRT临床可行,可能免除个体化ABM保护策略以减少血液学毒性。
研究设计与样本
- 研究纳入62例宫颈癌患者,分为训练集(n=32)和测试集(n=30),均具有治疗前FDG-PET/CT。
- ABM定义为骨盆骨髓(PBM)中SUV高于平均FDG-PET图像均值的亚体积(ABMAtlas)或个体PET定义的亚体积(ABMCustom),两者均形变至计划CT。
- 使用Dice系数测量ABMAtlas与ABMCustom重叠,并对30例测试患者比较三种IMRT计划(保护PBM、ABMAtlas或ABMCustom)的剂量学参数。
主要发现
- ABMAtlas与ABMCustom体积无显著差异(p=0.90),平均Dice系数0.75,提示一致性良好。
- 与保护PBM和ABMCustom的IMRT计划相比,ABMAtlas保护IMRT获得优良的靶区覆盖和正常组织保护,未降低ABMCustom剂量(平均ABMCustom剂量29.4Gy vs 27.1Gy vs 26.9Gy,p=0.10)。
- ABMAtlas保护IMRT的PTV覆盖和肠道保护略降低。
关键数值与推荐
- ABMAtlas与ABMCustom体积差异p=0.90,平均Dice系数0.75。
- 三种计划平均ABMCustom剂量分别为29.4Gy、27.1Gy、26.9Gy,p=0.10。
临床怎么用
- 基于图谱的ABM保护IMRT可作为宫颈癌放疗中减少血液学毒性的可行策略,无需个体化ABM定义。
- 需注意ABMAtlas保护计划可能轻微降低PTV覆盖和肠道保护。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To test the hypothesis that atlas-based active bone marrow (ABM)-sparing intensity modulated radiation therapy (IMRT) yields similar dosimetric results compared to custom ABM-sparing IMRT for cervical cancer patients. METHODS: We sampled 62 cervical cancer patients with pre-treatment FDG-PET/CT in training (n=32) or test (n=30) sets. ABM was defined as the subvolume of the pelvic bone marrow (PBM) with standardized uptake value (SUV) above the mean on the average FDG-PET image (ABMAtlas) vs. the individual's PET (ABMCustom). Both were deformed to the planning CT. Overlap between the two subvolumes was measured using the Dice coefficient. Three IMRT plans designed to spare PBM, ABMAtlas, or ABMCustom were compared for 30 test patients. Dosimetric parameters were used to evaluate plan quality. RESULTS: ABMAtlas and ABMCustom volumes were not significantly different (p=0.90), with a mean Dice coefficient of 0.75, indicating good agreement. Compared to IMRT plans designed to spare PBM and ABMCustom, ABMAtlas-sparing IMRT plans achieved excellent target coverage and normal tissue sparing, without reducing dose to ABMCustom (mean ABMCustom dose 29.4Gy vs. 27.1Gyvs. 26.9Gy, respectively; p=0.10); however, PTV coverage and bowel sparing were slightly reduced. CONCLUSIONS: Atlas-based ABM sparing IMRT is clinically feasible and may obviate the need for customized ABM-sparing as a strategy to reduce hematologic toxicity.
引用
- Li N, Noticewala SS, Williamson CW, et al. Feasibility of atlas-based active bone marrow sparing intensity modulated radiation therapy for cervical cancer. Radiother Oncol. 2017. PMID: 28528206. doi:10.1016/j.radonc.2017.02.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。